CLINICAL TRIALS PROFILE FOR ESCITALOPRAM OXALATE

All Clinical Trials for ESCITALOPRAM OXALATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00149825 ↗	Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome	Completed	National Institute of Mental Health (NIMH)	Phase 2	2004-06-01	This study will examine the effectiveness of a combination of antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression.
NCT00149825 ↗	Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome	Completed	Stanford University	Phase 2	2004-06-01	This study will examine the effectiveness of a combination of antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression.
NCT00222820 ↗	Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study	Completed	Mental Health Intervention Research Center (MHIRC)	Phase 4	2002-04-01	We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person's mood and anxiety and how these features affect a person's capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person's personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00222820 ↗	Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study	Completed	University of Pittsburgh	Phase 4	2002-04-01	We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person's mood and anxiety and how these features affect a person's capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person's personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00235508 ↗	Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder	Completed	Sunovion	Phase 4	2005-06-01	To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.

Clinical Trial Conditions for ESCITALOPRAM OXALATE

Condition Name

Condition Name for ESCITALOPRAM OXALATE
Intervention	Trials
Depression	6
Healthy	4
Major Depressive Disorder	4
Insomnia	2

Condition MeSH

Condition MeSH for ESCITALOPRAM OXALATE
Intervention	Trials
Depression	11
Depressive Disorder	9
Depressive Disorder, Major	6
Disease	3

Clinical Trial Locations for ESCITALOPRAM OXALATE

Trials by Country

Trials by Country for ESCITALOPRAM OXALATE
Location	Trials
United States	40
China	20
Brazil	2
India	2

Trials by US State

Trials by US State for ESCITALOPRAM OXALATE
Location	Trials
Illinois	3
Pennsylvania	3
California	3
North Carolina	2
New York	2

Clinical Trial Progress for ESCITALOPRAM OXALATE

Clinical Trial Phase

Clinical Trial Phase for ESCITALOPRAM OXALATE
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ESCITALOPRAM OXALATE
Clinical Trial Phase	Trials
Completed	13
Terminated	2
Unknown status	2

Clinical Trial Sponsors for ESCITALOPRAM OXALATE

Sponsor Name

Sponsor Name for ESCITALOPRAM OXALATE
Sponsor	Trials
Shirley Ryan AbilityLab	2
National Cancer Institute (NCI)	2
Forest Laboratories	2

Sponsor Type

Sponsor Type for ESCITALOPRAM OXALATE
Sponsor	Trials
Other	22
Industry	9
NIH	4